# US 2015/0089678 A1 · Non-human animals having a humanized signal-regulatory protein gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0089678 A1
- Document ID: US20150089678A1
- Status: Published application
- Kind: A1
- Application number: 14/493,745
- Filed: 2014-09-23
- Published: 2015-03-26
- Earliest claimed: 2013-09-23
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Andrew J. Murphy; O. Gavin Thurston; Bindu Varghese; Cagan Gurer
- Web page: https://patentgrep.com/patent/US20150089678A1

## CPC

- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- C12N 15/89: using microinjection
- C12N 15/902: {using homologous recombination}
- C12N 15/907: {in mammalian cells}
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2207/15: Humanized animals
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2217/052: inducing gain of function
- A01K 2217/054: inducing loss of function
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2227/10: Mammal
- A01K 2227/105: Murine
- A01K 2267/01: Animal expressing industrially exogenous proteins
- A01K 2267/0331: Animal model for proliferative diseases
- A01K 2267/0381: Animal model for diseases of the hematopoietic system
- A01K 2267/0387: Animal model for diseases of the immune system
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2887: {against CD20}
- C07K 2317/31: multispecific
- C07K 2319/00: Fusion polypeptide
- C12N 9/16: acting on ester bonds (3.1)
- C12N 2015/8518: {expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
- C12N 2015/8527: {for producing animal models, e.g. for tests or diseases}
- C12N 2015/8572: {Animal models for proliferative diseases, e.g. comprising an oncogene}
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12Y 301/03048: Protein-tyrosine-phosphatase (3.1.3.48)
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/5088: {of vertebrates}
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/10: involving cells
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRPα gene. Genetically modified mice are described, including mice that express a human or humanized SIRPα protein from an endogenous SIRPα locus.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method of making a mouse that expresses a SIRPα protein from an endogenous SIRPα locus, wherein the SIRPα protein comprises a human sequence, the method comprising:
(a) targeting an endogenous SIRPα locus in a mouse ES cell with a genomic fragment comprising a nucleotide sequence that encodes a human SIRPα protein in whole or in part;
(b) obtaining a modified mouse ES cell comprising an endogenous SIRPα locus that comprises the human sequence of (a); and,
(c) creating a mouse using the modified ES cell of (b).

### Claim 21 (depends on 20)

The method of claim 20, wherein the human nucleotide sequence comprises exons 2, 3 and 4 of a human SIRPα gene.

### Claim 22 (depends on 20)

The method of claim 20, wherein the human nucleotide sequence encodes amino acid residues 28-362 of a human SIRPα protein.

### Claim at position 5

23-25. (canceled)

### Claim 26

A method of engrafting human cells into a mouse, comprising steps of:
(a) providing a mouse whose genome comprises a SIRPα gene that encodes an extracellular portion of a human SIRPα protein linked to an intracellular portion of a mouse SIRPα protein; and
(b) transplanting one or more human cells into the mouse.

### Claim 27 (depends on 26)

The method of claim 26, further comprising a step of:
(c) assaying engraftment of the one or more human cells in the mouse.

### Claim 28 (depends on 27)

The method of claim 27, wherein the step of assaying comprises comparing the engraftment of the one or more human cells to the engraftment in one or more wild-type mice or in one or more mice whose genome does not comprise a SIRPα gene that encodes an extracellular portion of a human SIRPα protein linked to an intracellular portion of a mouse SIRPα protein.

### Claim 29 (depends on 26)

The method of claim 26, wherein the SIRPα gene comprises exons 2, 3, and 4 of a human SIRPα gene.

### Claim 30 (depends on 26)

The method of claim 26, wherein the extracellular portion of a human SIRPα protein comprises amino acids corresponding to residues 28-362 of a human SIRPα protein that appears in Table 3.

### Claim 31 (depends on 26)

The method of claim 26, wherein the human cells are hematopoietic stem cells.

### Claim 32 (depends on 26)

The method of claim 26, wherein the human cells are transplanted intravenously, intraperitoneally, or subcutaneously.

### Claim at position 13

33-34. (canceled)

### Claim 35

A method comprising,
(a) providing one or more cells whose genome includes a SIRPα gene that encodes an extracellular portion of a human SIRPα protein linked to an intracellular portion of a mouse SIRPα protein;
(b) incubating the one or more cells of step (a) with a labeled substrate; and
(c) measuring phagocytosis of the labeled substrate by the one or more cells of step (b).

### Claim 36 (depends on 35)

The method of claim 35, wherein the cells of step (a) are mouse cells.

### Claim 37 (depends on 35)

The method of claim 35, wherein the SIRPα gene is operably linked to a mouse SIRPα promoter.

### Claim 38 (depends on 35)

The method of claim 35, wherein the SIRPα gene comprises exons 2, 3, and 4 of a human SIRPα gene.

### Claim 39 (depends on 35)

The method of claim 35, wherein the substrate is fluorescently labeled or labeled with an antibody.

### Claim 40

(canceled)

### Claim 41 (depends on 35)

The method of claim 35, wherein the substrate is one or more red blood cells or one or more bacterial cells.

### Claim 42

(canceled)

### Claim 43

A method comprising,
(a) providing a mouse whose genome includes a SIRPα gene that encodes an extracellular portion of a human SIRPα protein linked to an intracellular portion of a mouse SIRPα protein;
(b) exposing the mouse to an antigen; and
(c) measuring phagocytosis of the antigen by one or more cells of the mouse.

### Claim 44 (depends on 43)

The method of claim 43, wherein the SIRPα gene is operably linked to a mouse SIRPα promoter.

### Claim 45 (depends on 43)

The method of claim 43, wherein the SIRPα gene comprises exons 2, 3, and 4 of a human SIRPα gene.

### Claim 46 (depends on 43)

The method of claim 43, wherein the step of exposing comprises exposing the mouse to an antigen that is fluorescently labeled.

### Claim 47 (depends on 43)

The method of claim 43, wherein the step of exposing comprises exposing the mouse to one or more cells that comprise the antigen.

### Claim 48 (depends on 47)

The method of claim 47, wherein the step of exposing comprises exposing the mouse to one or more human cells comprising the antigen or to one or more bacterial cells comprising the antigen.

### Claim 49

A method of assessing the therapeutic efficacy of a drug targeting human cells, comprising:
providing a mouse whose genome comprises a SIRPα gene that encodes an extracellular portion of a human SIRPα protein linked to an intracellular portion of a mouse SIRPα protein;
transplanting one or more human cells into the mouse;
administering a drug candidate to said mouse; and
monitoring the human cells in the mouse to determine the therapeutic efficacy of the drug candidate.

### Claim 50 (depends on 49)

The method of claim 49, wherein the human cells are cancer cells, and said drug candidate is an anti-cancer drug candidate.

### Claim 51 (depends on 49)

The method of claim 49, wherein said drug candidate is an antibody.

### Claim 52 (depends on 50)

The method of claim 50, wherein said mouse further comprises human immune cells.

### Claim 53 (depends on 52)

The method of claim 52, wherein said drug candidate is a bispecific antibody that binds to an antigen on the human immune cells and an antigen on the transplanted human cancer cells.
